Please assess the completion status of the following clinical trial:

Trial Title: Genicular Nerve Block in Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* juvenile idiopathic arthritis with persistent knee arthritis~* age below 16~Exclusion Criteria:~* severe knee osteoarthritis~* peripheral neuropathy,~* psoriatic arthritis,~* those under anticoagulant therapy, skin infection,~* prior knee injection in the last 3 months3~* those who have an allergy to Bupivacaine

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Active genicular nerve block group (Type: ACTIVE_COMPARATOR): group 1 will receive genicular nerve block. The injection and US examination will be done by two experienced sonographers. They were blinded to clinical data. Patients will also be blinded for the injected substance. Each point will be injected with 2 ml of Lidocaine hydrochloride 2 % (Xylocaine, Astrazeneca). The injection will be done using the 3 point technique (superior medial, superior lateral, and inferior medial genicular nerves).
- intra-articular steroid injection group (Type: OTHER): while group 2 received intra-articular triamcinolone under ultrasound guidance and through injecting the supra-patellar bursa.

Based on this trial design, predict the completion outcome and termination type (if applicable).